Related references
Note: Only part of the references are listed.Evaluation of PD-1 and PD-L1 expression in canine urothelial carcinoma cell lines
Christopher J. Pinard et al.
VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY (2022)
Development of Monoclonal Antibodies Targeting Canine PD-L1 and PD-1 and Their Clinical Relevance in Canine Apocrine Gland Anal Sac Adenocarcinoma
Lucia Minoli et al.
CANCERS (2022)
Highly efficient hybridoma generation and screening strategy for anti-PD-1 monoclonal antibody development
Tanapati Phakham et al.
SCIENTIFIC REPORTS (2022)
Canine osteosarcoma checkpoint expression correlates with metastasis and T-cell infiltrate
Matthew J. Cascio et al.
VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY (2021)
Cross-Reactivity and Functionality of Approved Human Immune Checkpoint Blockers in Dogs
Stanislav Pantelyushin et al.
CANCERS (2021)
PD-L1 immunohistochemistry for canine cancers and clinical benefit of anti-PD-L1 antibody in dogs with pulmonary metastatic oral malignant melanoma
Naoya Maekawa et al.
NPJ PRECISION ONCOLOGY (2021)
PD-1, PD-L1, and PD-L2 Gene Expression and Tumor Infiltrating Lymphocytes in Canine Melanoma
Valentina B. Stevenson et al.
VETERINARY PATHOLOGY (2021)
Prognostic Value of PD-L1, PD-1 and CD8A in Canine Diffuse Large B-Cell Lymphoma Detected by RNAscope
Luca Aresu et al.
VETERINARY SCIENCES (2021)
The future of cancer immunotherapy: microenvironment-targeting combinations
Yonina R. Murciano-Goroff et al.
CELL RESEARCH (2020)
The Role of PD-1 in Acute and Chronic Infection
Jil M. Jubel et al.
FRONTIERS IN IMMUNOLOGY (2020)
Development of canine PD-1/PD-L1 specific monoclonal antibodies and amplification of canine T cell function
Jin Wook Choi et al.
PLOS ONE (2020)
Increased programmed death ligand (PD-L1) and cytotoxic T-lymphocyte antigen-4 (CTLA-4) expression is associated with metastasis and poor prognosis in malignant canine mammary gland tumours
Harsha Ariyarathna et al.
VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY (2020)
A pilot clinical study of the therapeutic antibody against canine PD-1 for advanced spontaneous cancers in dogs
Masaya Igase et al.
SCIENTIFIC REPORTS (2020)
Quantification and prognostic value of programmed cell death ligand-1 expression in dogs with diffuse large B-cell lymphoma
Lisbeth A. Ambrosius et al.
AMERICAN JOURNAL OF VETERINARY RESEARCH (2018)
Immune evasion via PD-1/PD-L1 on NK cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCL
Frank Vari et al.
BLOOD (2018)
Development and characterization of monoclonal antibodies against canine PD-1 and PD-L1
Yuki Nemoto et al.
VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY (2018)
Immune regulation of canine tumour and macrophage PD-L1 expression
G. Hartley et al.
VETERINARY AND COMPARATIVE ONCOLOGY (2017)
Programmed death ligand 1 is expressed in canine B cell lymphoma and downregulated by MEK inhibitors
S. R. Kumar et al.
VETERINARY AND COMPARATIVE ONCOLOGY (2017)
A canine chimeric monoclonal antibody targeting PD-L1 and its clinical efficacy in canine oral malignant melanoma or undifferentiated sarcoma
Naoya Maekawa et al.
SCIENTIFIC REPORTS (2017)
Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma
Aleix Prat et al.
CANCER RESEARCH (2017)
Immunohistochemical Analysis of PD-L1 Expression in Canine Malignant Cancers and PD-1 Expression on Lymphocytes in Canine Oral Melanoma
Naoya Maekawa et al.
PLOS ONE (2016)
Immune evasion in cancer: Mechanistic basis and therapeutic strategies
Dass S. Vinay et al.
SEMINARS IN CANCER BIOLOGY (2015)
Expression of PD-L1 on Canine Tumor Cells and Enhancement of IFN-γ Production from Tumor-Infiltrating Cells by PD-L1 Blockade
Naoya Maekawa et al.
PLOS ONE (2014)
PD-L1 Expression in Triple-Negative Breast Cancer
Elizabeth A. Mittendorf et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Expression of programmed death 1 ligands by murine T cells and APC
T Yamazaki et al.
JOURNAL OF IMMUNOLOGY (2002)
PD-L2 is a second ligand for PD-I and inhibits T cell activation
Y Latchman et al.
NATURE IMMUNOLOGY (2001)